Market revenue in 2023 | USD 97.4 million |
Market revenue in 2030 | USD 129.0 million |
Growth rate | 4.1% (CAGR from 2023 to 2030) |
Largest segment | New born screening (nbs) |
Fastest growing segment | CRO/Research |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | New Born Screening (NBS), Infectious Disease Testing, Therapeutic Drug Monitoring, CRO/Research, Other Applications, Forensics |
Key market players worldwide | Qiagen NV, PerkinElmer, Roche Holding AG, Shimadzu Corp, Ahlstrom-Munksjö, Danaher Corp, Centogene NV Ordinary Shares, Eastern Business Forms, Archimedlife |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dried blood spot collection cards market will help companies and investors design strategic landscapes.
New born screening (nbs) was the largest segment with a revenue share of 24.02% in 2024. Horizon Databook has segmented the Europe dried blood spot collection cards market based on new born screening (nbs), infectious disease testing, therapeutic drug monitoring, cro/research, other applications, forensics covering the revenue growth of each sub-segment from 2018 to 2030.
Europe accounted for the second-largest market share in 2022 and is considered to have a matured market for DBS testing. Rise in the prevalence of chronic and infectious diseases and growing investments for development of advanced diagnostics solutions are expected to drive the market in this region.
For instance, in February 2022, Roche announced the initiation of Spinal Muscular Atrophy (SMA) screening in newborns across Europe. Various European countries have made progress in adopting SMA screening recommendations. Countries such as Belgium, Netherlands, Slovenia, Poland, and Germany approved SMA screening.
Moreover, the presence of well-established biotechnology industry and research institutes has increased the demand for DBS testing for therapeutic drug monitoring and CRO/research applications. In 2020, the COVID-19 pandemic created high demand for effective diagnosis solutions, including DBS collection cards, in key European countries such as Italy, the UK, France, Spain, and Germany to conduct mass testing for controlling the pandemic.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe dried blood spot collection cards market , including forecasts for subscribers. This continent databook contains high-level insights into Europe dried blood spot collection cards market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account